NCT05042193View on ClinicalTrials.gov

A Prospective Virtual Study to Evaluate the Longevity of IgG Antibodies in Individuals Exposed to COVID-19

CompletedOBSERVATIONAL
Enrollment

1,883

Participants

Timeline

Start Date

March 19, 2021

Primary Completion Date

May 31, 2022

Study Completion Date

June 14, 2022

Conditions
SARS-CoV-2 Acute Respiratory Disease
Interventions
OTHER

SARS-CoV-2

Observational

Trial Locations (1)

78703

Everlywell, Inc, Austin

Sponsors

Lead Sponsor

Everly Health
All Listed Sponsors
lead

Everly Health

INDUSTRY

NCT05042193 - A Prospective Virtual Study to Evaluate the Longevity of IgG Antibodies in Individuals Exposed to COVID-19 | Biotech Hunter | Biotech Hunter